Our Story

Cresilon’s Story

Constantly experimenting with natural materials in the lab as a young adult, Joe Landolina developed an adhesive hemostatic gel composed of plant-based polymers that could support the natural clotting process.

Our team is dedicated to one mission:
SAVING LIVES

To refine and manufacture the gel technology he invented, Joe, with his partner, Isaac Miller, founded the Brooklyn-based medical device company, Cresilon, Inc.

They recognized that stopping a bleed effectively remained a critical need in both veterinary and human medicine.
Based on Joe’s invention, our proprietary product VETIGEL® was developed out of the need for a faster, more reliable solution in hemostasis for veterinarians performing both routine treatments and complex operations.

As we expand applications for our principal gel technology, our team is connected by one shared mission – saving lives. We aim to do this by improving wound care and advancing the standard of its medical treatment.

2010 Origin

NYU Innovation Roots

NYU students Joe Landolina and Isaac Miller win first place in NYU’s InnoVention Competition and establish Cresilon as a biotechnology company.

2013–2018 Foundation

Brooklyn Headquarters + Technology Expansion

Establish corporate headquarters in Brooklyn, New York, and advance proprietary hemostatic technology through an expanding patent portfolio and real-world clinical application, while scaling through targeted talent acquisition.

2018–2020 Scale

GMP Manufacturing in Brooklyn

Commission the first and only GMP-certified manufacturing facility in Brooklyn, enabling scalable production of proprietary hemostatic technology and supporting preparations for the company’s first commercial launch.

2020 Launch

VETIGEL^® Introduced

Launch VETIGEL®, the first hydrogel product to the veterinary market, designed to rapidly stop bleeding within seconds.

2021–2023 Growth

Global Reach + First FDA Clearance

Expand VETIGEL® globally via direct domestic sales and a growing international distributor network, supporting over 65,000 veterinary procedures worldwide. Achieve the company’s first FDA clearance, an important milestone toward human healthcare applications.

2024–2025 Next

TRAUMAGEL^® FDA 510(k) Clearance

Receive FDA 510(k) clearance for TRAUMAGEL®, a hydrogel designed to control moderate to severe external traumatic bleeding. Following introduction, TRAUMAGEL® is adopted by first responders, emergency physicians, and trauma personnel.